mRNA Therapy Could Repair Damaged Lungs
A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to UPenn researchers.
Tag: mRNA
All
Latest
mRNA Therapy Could Repair Damaged Lungs
A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to UPenn researchers.
Read More
Pfizer and BioNTech Report Mixed Results in Phase 3 Flu-COVID Vaccine Trial
The vaccine candidate showed strong responses against influenza A and COVID-19 but did not meet its goal for influenza B.
Read More
Moderna Reports Positive Phase 3 Results for Flu-COVID Combo Vaccine
mRNA-1083 elicited higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older.
Read More
FDA Approves mRNA-based RSV Vaccine for Older Adults
The vaccine demonstrated 83.7% efficacy in preventing RSV lower respiratory tract disease in adults aged 60 and older.
Read More
Researchers Say Their Experimental Bird Flu Vaccine Could Prevent Human Infections
Preclinical results suggest the Penn researchers’ mRNA vaccine could limit the impact of avian flu pandemics.
Read More
COVID-19 Vaccines Provides Long-lasting Antibody Response
Researchers say the study results challenge the idea that mRNA-based vaccine immunity wanes quickly.
Read More
Investigational mRNA Cystic Fibrosis Treatment Granted Orphan Drug Designation
The drug candidate utilizes a lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs.
Read More
2023 Nobel Prize in Medicine Awarded to Trailblazers of mRNA Research
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19 during the pandemic that began in early 2020.
Read More
Cystic Fibrosis mRNA Therapeutic Candidate Gets Funding Boost
The Cystic Fibrosis Foundation is investing up to $9 million in additional funds in Arcturus Therapeutics to test ARCT-032, an inhaled messenger RNA therapeutic candidate that could treat the underlying cause of cystic fibrosis in all people living with the disease.
Read More
COVID-19 Vaccines Induce Immune Response in Nasal Cavity
A new study has found that SARS-CoV-2 mRNA vaccination induces an immune response in the mucosal lining of the nasal cavity, offering new insights into potential vaccine strategies in the future.
Read More
Therapy Derived from Skin Cells May Be Able to Treat Injured Lungs
The hope is that a drop of solution containing these nanocarriers, delivered to the lungs via the nose, could treat acute respiratory distress syndrome.
Read More
Clinical Trial of mRNA Universal Flu Vaccine Candidate Begins
The phase 1 trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.
Read More
Researchers Develop mRNA Vaccine Effective Against Deadly Bacteria
Researchers say the new technology can enable rapid development of effective vaccines for bacterial diseases, including those caused by antibiotic-resistant bacteria.
Read More
Aerosolized mRNA Pneumonia Treatment Improved Symptoms in Preclinical Study
mRNA encoding immunomodulatory proteins IκBα-SR and SOD3 ameliorated symptoms in a bacterial pneumonia model.
Read More
AAHI Awarded $9.9M to Develop Nasal Spray Influenza Vaccine
The 40-month project may culminate in a prototype bivalent vaccine candidate that is effective against both the H5N1 and H7N9 strains of influenza, according to Access to Advanced Health Institute.
Read More
How an mRNA Flu Vaccine Could be a Game Changer
An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals.
Read More
NIH Grant Funds Cancer Prevention mRNA Vaccine Research
A multidisciplinary team of Weill Cornell Medicine researchers have received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.
Read More